Highlights Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-12 pm EST			5-day change	1st Jan Change
40.51 ^USD	+2.32%		+1.71%	+17.73%

Dec. 08	Harmony Biosciences Holdings, Inc. Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome	CI
Dec. 01	Mizuho Raises Price Target on Harmony Biosciences Holdings to $46 From $39, Keeps Outperform Rating	MT

Highlights

Harmony Biosciences Holdings, Inc. Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome	Dec. 08	CI
Harmony Biosciences Holdings, Inc. Announces Positive Results from the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation	Nov. 24	CI
Harmony Biosciences Holdings, Inc. Announces Initiation of First-In-Human Study with Potential Best-In-Class Orexin 2 Receptor Agonist (Bp1.15205) for Central Disorders of Hypersomnolence	Nov. 19	CI
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	Nov. 04	CI
Harmony Biosciences' Q3 Adjusted Net Income, Revenue Rise; Full-Year 2025 Revenue Guidance Raised	Nov. 04	MT
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.	Nov. 04	CI
Earnings Flash (HRMY) Harmony Biosciences Holdings, Inc. Reports Q3 Revenue $239.5M, vs. FactSet Est of $226.9M	Nov. 04	MT
Earnings Flash (HRMY) Harmony Biosciences Holdings, Inc. Posts Q3 Adjusted EPS $1.08 per Share	Nov. 04	MT
Harmony Biosciences Q3 revenue growth beats estimates on increase in patients	Nov. 04	RE
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	Oct. 23	MT
Harmony Biosciences Reports Q3 Preliminary Revenue, Raises 2025 Revenue Guidance	Oct. 23	MT
(HRMY) Harmony Biosciences Expects Full Year 2025 Revenue Range $845M-$865M, vs. FactSet Est of $841.6M	Oct. 23	MT
Harmony Biosciences Holdings, Inc. Raises Revenue Guidance for the Year 2025	Oct. 23	CI
Sector Update: Health Care Stocks Slide Thursday Afternoon	Sep. 25	MT
Harmony Biosciences Holdings, Inc. Provides Update from its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome	Sep. 24	CI
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	Aug. 05	CI
Harmony Biosciences Q2 Adjusted Earnings, Revenue Rise; Reiterates 2025 Revenue Outlook	Aug. 05	MT
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.	Aug. 05	CI
Harmony Biosciences Q2 revenue misses estimates	Aug. 05	RE
Earnings Flash (HRMY) Harmony Biosciences Holdings, Inc. Reports Q2 Revenue $200.5M, vs. FactSet Est of $204.2M	Aug. 05	MT
Earnings Flash (HRMY) Harmony Biosciences Holdings, Inc. Posts Q2 Adjusted EPS $0.92 per Share	Aug. 05	MT
Harmony Biosciences Holdings, Inc. Reaffirms Revenue Guidance for the Full Year 2025	Aug. 05	CI
Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025	Jun. 11	CI
Harmony Biosciences, Lupin Settle Lawsuit Over Generic Version of Narcolepsy Drug	Jun. 05	MT
Harmony Biosciences Q1 Adjusted Earnings, Revenue Increase; 2025 Sales Outlook Reiterated	May. 06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Pharmaceuticals

Highlights

Filters